Lowest Price Guaranteed From USD 4,899
Published
March 2020
Pages
210
View Count
14399
Example Insights
Report Description
The Chinese pharmaceutical contract manufacturing services market is expected to be worth $5.5 billion in 2020 and is projected to reach $13 billion by 2030, growing at a CAGR of ~9%. Small molecule drugs represent nearly 90% of pharmaceutical products available in the market. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 drugs, of which, 67% were small molecules. However, drug development and manufacturing is a cost intensive process, and is, at times, characterized by the need for advanced capabilities and specialized facilities, which are not possible for all developer companies to build in-house. This has compelled many of the smaller companies to outsource a significant part of their manufacturing operations to contract service providers. Pharmaceutical contract manufacturing organizations (CMOs) offer a wide range of services, ranging from process R&D, and clinical / commercial scale manufacturing of APIs, intermediates and FDFs. Some of the benefits of engaging manufacturing service providers include access to larger production capacities, cost savings (for innovator companies) and reductions in time-to-market. In this context, the advantages of outsourcing to emerging global regions, especially in Asia, are well known. A number of western drug developers have already demonstrated the preference to outsource their manufacturing operations to CMOs or CDMOs in China.
Over the past few decades, the pharmaceutical market in China has evolved into the second largest in the world; as per certain industry experts, it is estimated to surpass USD 300 billion by the end of 2020. Similarly, the contract manufacturing market in the region has also grown into a prominent and promising segment of the pharmaceutical industry. The relatively lower manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, have led to the establishment of various pharmaceutical manufacturing facilities in China by both Chinese and non-China based service providers. The number of FDA approved API manufacturing facilities in the region has doubled during the period 2010-2019. In fact, as of October 2019, 13% of FDA approved pharmaceutical manufacturing facilities are situated in China. These service providers are focused on investing in the development of the necessary capabilities and capacity to stay ahead of the competition in this field. In light of the aforementioned facts, China has been one of the top preferences of pharmaceutical companies for API and FDF manufacturing projects, since the past few years.
We believe that, the changing supply chain scenario due to the recent COVID-19 outbreak is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. Having said that, the steps being taken by the pharma players and contract manufacturers are likely to help stakeholders absorb this impact. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.
Several recent developments have taken place in the field of China pharmaceutical contract manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall pharmaceutical drugs market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large. To account for the uncertainties associated with the growth of the pharmaceutical drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing services market in China, in the short-mid and long term.
Chapter 3 is a general introduction to various type of manufacturers engaged in the pharmaceutical domain. It also includes a brief overview on the concept of contract manufacturing and a general discussion on the evolution of contract services in the pharmaceutical industry. The chapter features an exhaustive list of services offered by CMOs. Further, it highlights the current contract manufacturing scenario in China, along with the advantages and disadvantages associated with choosing a China based CMO as a partner.
Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it highlights the information on the key manufacturing challenges associated with small molecules and large molecules.
Chapter 5 provides an overview of the pharmaceutical contract manufacturing landscape of companies that claim to offer small molecule API, intermediate and FDF manufacturing services. It includes analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, type of product (APIs, intermediates and FDFs), type of FDFs, type of packaging (primary packaging and secondary packaging), and number of China-based manufacturing facilities.
Chapter 6 provides a detailed landscape of pharmaceutical manufacturing facilities in China. It includes analysis and map representations based on location of these facilities, highlighting key provinces as manufacturing hubs.
Chapter 7 features a brief discussion on the regulatory guidelines related to the pharmaceutical manufacturing in China. It also highlights points related to the various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
Chapter 8 includes detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile features a brief overview of the company, details related to its manufacturing-related service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
Chapter 9 provides a detailed analysis of pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] facility investment analysis with detailed information on R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework presenting the summary of manufacturing initiatives undertaken by big pharma players in China, and [C] heat map representation representing the year-wise distribution of the initiatives undertaken by each company.
Chapter 10 represents a case study of the key recent activities of the CMOs from 2017 to February 2020 (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs. It includes analysis based on several parameters, such as year of partnership, type of partnership and geographical activity of the partnerships.
Chapter 11 features an estimate of the overall installed reactor capacity of CMOs. The analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).
Chapter 12 presents a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
Chapter 13 features an elaborate market forecast analysis highlighting the likely growth of pharmaceutical contract manufacturing market in China, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 14 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.
Chapter 15 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of the Pharmaceutical Contract Manufacturing
3.3. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.3.1. Traditional CMOs
3.3.2. Modern CMOs
3.4 Need for Outsourcing in the Pharmaceutical Industry
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs
4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.4.1. Analysis by Type of Product and Location of Headquarters
5.2.5. Analysis by Highest Scale of Operation
5.2.6. Analysis by Type of FDF
5.2.6.1. Analysis by Type of Solid FDF
5.2.6.2. Analysis by Type of Liquid FDF
5.2.6.3. Analysis by Type of Powder FDF
5.2.6.4. Analysis by Type of Semi-Solid FDF
5.2.6.5. Analysis by Type of FDF and Region
5.2.7. Analysis by Type of Primary Packaging
5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.4.1. Analysis by Type of Product and Region
5.3.5. Analysis by Highest Scale of Operation
5.3.6. Analysis by Type of FDF
5.3.6.1. Analysis by Type of Solid FDF
5.3.6.2. Analysis by Type of Liquid FDF
5.3.6.3. Analysis by Type of Powder FDF
5.3.6.5. Analysis by Type of FDF and Region
6. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Pharmaceutical CMO Manufacturing Facilities in China
6.2.1. Facilities in Eastern China
6.2.1.1. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Location of Facility
6.2.1.2. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Company Size and Type of Product
6.2.2. Facilities in Northern China
6.2.2.1. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Location of Facility
6.2.2.2. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Company Size and Type of Product
6.2.3. Facilities in Southern China
6.2.3.1. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Location of Facility
6.2.3.2. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Company Size and Type of Product
7. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook
8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook
8.10. Shanghai Acebright Pharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.4. Recent Developments and Future Outlook
9. BIG PHARMA INITIATIVES IN CHINA
9.1. Chapter Overview
9.2. Big Pharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year of Initiative
9.2.4. Analysis by Type of Initiative
9.3. Benchmark Analysis of Big Pharmaceutical Players
9.3.1. Harvey Ball Analysis: Summary of Investments Made
9.3.2. Geographical Analysis by Investments Made (Facility Specific)
10. CASE STUDY: RECENT PARTNERSHIP TRENDS
10.1. Chapter Overview
10.2. Partnership Models
10.3. CMOs with Manufacturing Facilities in China: List of Recent Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Geography
10.4. CMOs with Manufacturing Facilities in China: Mapping Partnerships
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1. Capacity Analysis: Eastern China
11.3.2.2. Capacity Analysis: Southcentral China
11.3.2.3. Capacity Analysis: Northern China
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030
13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products
13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030
13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies
13.8. Concluding Remarks
14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak
15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. Wuxi AppTec
15.2.1.2. Porton Pharma Solutions
15.2.1.3. Lonza
15.2.2 Impact on China Pharmaceutical CMO Market Opportunity
15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long Term Steps
15. CONCLUSION
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Outsourcing across Various Components of the Pharmaceutical Value Chain
Figure 3.2 Range of Services Offered by CMOs
Figure 4.1 Small Molecule and Large Molecule Drugs: Comparison of Key Characteristics
Figure 4.2 Small Molecules versus Large Molecule: Comparison of Manufacturing Process
Figure 5.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Figure 5.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.6 Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Location of Headquarters
Figure 5.7 Chinese Pharmaceutical CMOs: Highest Scale of Operation
Figure 5.8 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.9 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.10 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.11 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.12 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Figure 5.13 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 5.14 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Figure 5.15 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.16 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.17 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.18 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Figure 5.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Geography
Figure 5.21 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Figure 5.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.23 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.24 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.25 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.26 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 6.1 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Eastern China
Figure 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Company Size and Type of Product
Figure 6.3 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Northern China
Figure 6.4 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Company Size and Type of Product
Figure 6.5 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Southern China
Figure 6.6 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size and Type of Product
Figure 7.1 Health Authorities in China and Affiliated Organizations of the CFDA
Figure 7.2 Organizational Structure of the CDE
Figure 7.3 Responsibilities of the Contract Giver
Figure 7.4 Important Aspects of the Contract
Figure 9.1 Big Pharma Benchmarking: Distribution by Number of Initiatives
Figure 9.2 Big Pharma Players: Distribution by Year of Initiative
Figure 9.3 Big Pharma Players: Distribution by Company and Year of Initiative
Figure 9.4 Big Pharma Players: Distribution by Type of Initiative
Figure 9.5 Harvey Ball Analysis: Summary of Investments Made
Figure 9.6 Big Pharma Players: Geographical Distribution by Investments Made (Facility Specific)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Local and International Distribution
Figure 10.4 Partnerships Landscape: Distribution by Year of Collaboration, Type of Collaboration and Collaborator
Figure 11.1 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Figure 11.2 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Figure 11.3 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Figure 11.4 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Figure 11.5 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Figure 12.1 China Pharmaceutical Contract Manufacturing Services Market: SWOT Analysis
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.2 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Geography: Base Scenario (USD Billion)
Figure 13.3 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.4 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.5 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.6 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Type of Product (USD Billion)
Figure 13.7 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.8 API Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.9 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.10 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.11 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.12 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.13 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.14 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.15 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.16 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.17 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2020-2030, Base Scenario (USD Billion)
Figure 13.18 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Figure 13.19 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Figure 13.20 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Figure 13.21 Drug product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Figure 13.22 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2020-2030, Base Scenario (USD Billion)
Figure 13.23 Clinical Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.24 Commercial Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.25 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2020-2030, Base Scenario (USD Billion)
Figure 13.26 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Small Companies: Base Scenario (USD Billion)
Figure 13.27 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Mid-sized Companies: Base Scenario (USD Billion)
Figure 13.28 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Large / Very Large Companies: Base Scenario (USD Billion)
Figure 14.1 Pharmaceutical Contract Manufacturing Services Market in China, 2015-2030: COVID Impact Scenario (USD Billion)
Figure 14.2 Financial Leadership vs Strategic Leadership Matrix: Evaluation of Preparedness of Companies
Figure 15.2 China Pharmaceutical Contract Manufacturing Services Market: Key Takeaways
Table 3.1 Preferred Locations for Pharmaceutical CMO / CDMO Services
Table 4.1 Small Molecule and Large Molecule Drugs: Comparison of Development Characteristics
Table 5.1 List of Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Location of Headquarters, Type of Product and Scale of Operation
Table 5.2 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 5.3 List of Chinese Pharmaceutical CMOs: Information on Packaging Service
Table 5.4 List of Non-Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Headquarter Location and Type of Product and Scale of Operation
Table 5.5 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 6.1 Pharmaceutical CMO Manufacturing Facilities in China: Information on Location of Facilities
Table 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.3 Pharmaceutical CMO Manufacturing Facilities in Northern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.4 Pharmaceutical CMO Manufacturing Facilities in Southern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 8.1 2-Y Chem: Company Overview
Table 8.2 2Y-Chem: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.3 Aurisco Pharmaceutical: Company Overview
Table 8.4 Aurisco Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.5 ChemPartner: Company Overview
Table 8.6 ChemPartner: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.7 Dorrapharma: Company Overview
Table 8.8 Dorrapharma: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.9 Hubei Biocasue Pharmaceutical: Company Overview
Table 8.10 Hubei Biocasue Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.11 Infoark: Company Overview
Table 8.12 Ningbo Menovo Pharmaceutical: Company Overview
Table 8.13 Shandong Xinhua Pharmaceutical: Company Overview
Table 8.14 Shandong Xinhua Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.15 Shanghai Acebright Pharmaceuticals: Company Overview
Table 8.16 STA Pharmaceutical: Company Overview
Table 8.17 STA Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.18 Zhejiang Huahai Pharmaceutical: Company Overview
Table 8.19 Zhejiang Huahai Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 9.1 Big Pharmaceutical Players: List of Initiatives
Table 10.1 List of Partnerships, 2014-Q1 2019
Table 10.2 List of Partnerships: Information on Headquarter Location of Parent and Partner Company
Table 11.1 China Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 11.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Chinese Manufacturing Facility(s)
Table 16.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Table 16.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.6 Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.7 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.8 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.9 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.10 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.11 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Table 16.12 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Table 16.13 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.14 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.15 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.16 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Table 16.17 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.18 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.21 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.23 Pharmaceutical CMO Manufacturing Facilities in Eastern China:
Table 16.24 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Type of Product
Table 16.25 Pharmaceutical CMO Manufacturing Facilities in Northern
Table 16.26 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Type of Product
Table 16.27 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size
Table 16.28 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Type of Product
Table 16.29 Big Pharma Players: Distribution by Number of Initiatives
Table 16.30 Big Pharma Players: Distribution by Year of Initiative
Table 16.31 Big Pharma Players: Distribution by Type of Initiative
Table 16.33 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.35 Partnerships and Collaborations: Local and International Distribution
Table 16.36 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Table 16.37 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Table 16.38 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Table 16.39 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Table 16.40 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Table 16.41 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.42 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Geography: Base Scenario (USD Billion)
Table 16.43 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.44 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.45 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.46 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Type of Product (USD Billion)
Table 16.47 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.48 API Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.49 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.50 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.51 API Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.53 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.52 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.54 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.55 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.56 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.57 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2025 and 2030, Base Scenario (USD Billion)
Table 16.58 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Table 16.59 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Table 16.60 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Table 16.61 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Table 16.62 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2025 and 2030, Base Scenario (USD Billion)
Table 16.63 Clinical Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.64 Commercial Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.65 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2025 and 2030, Base Scenario (USD Billion)
Table 16.66 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies: Base Scenario (USD Billion)
Table 16.67 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-Sized Companies: Base Scenario (USD Billion)
Table 16.68 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies: Base Scenario (USD Billion)
The following companies and organizations have been mentioned in the report: